Self-Monitoring Your Sense of Smell May Help Detect Coronavirus
REHOVOT, ISRAEL—April 2, 2020—Along with fever, cough, and shortness of breath, many COVID-19 patients report a temporary loss of sense of smell. It appears that olfactory loss is significantly greater in coronavirus patients compared to the loss often experienced during a cold and, less commonly, in influenza (non-COVID-19) patients. In some countries, such as France, a patient who claims to have sudden onset of olfactory loss will be diagnosed as a coronavirus patient – without even being tested.
A similar approach is being considered in the U.K. Based on this data, Weizmann Institute of Science investigators, in collaboration with Israel’s Edith Wolfson Medical Center, developed SmellTracker – an online platform that enables self-monitoring of one’s sense of smell – in order to detect early signs of COVID-19, or in the absence of other symptoms.
Prof. Noam Sobel’s laboratory in the Weizmann Institute’s Department of Neurobiology specializes in olfactory research. The researchers previously developed a mathematical model that accurately characterizes a person’s unique sense of smell – a kind of individual “olfactory fingerprint.”
SmellTracker, based on this algorithm, is an online test that guides users on how to map their sense of smell using five scents found in every home (spices, vinegar, toothpaste, various scent extracts, peanut butter, etc.). The smell test takes about five minutes and is able to monitor sudden changes in odor perception that may be an early indication of COVID-19 onset. The researchers report that the new tool has already successfully identified potential coronavirus cases, which were later confirmed. Aside from personal monitoring, the test will be beneficial because, as more data is collected, the researchers are more likely to be able to characterize a unique olfactory fingerprint for the early detection of COVID-19.
Eight strains of coronavirus
Olfactory loss was not commonly reported in the city of Wuhan, China, where the first coronavirus outbreak took hold. Nevertheless, preliminary studies conducted in several countries, including Israel and Iran, show that this symptom appears in about 60% of patients.
Scientists estimate that there are currently eight active strains of the virus, and Sobel’s lab believes that olfactory loss may be a differentiating symptom of the various strains. If this turns out to be true, the SmellTracker will be able to map the various outbreaks geographically.
Besides SmellTracker, the Sobel lab is distributing “scratch and smell” kits to confirmed coronavirus patients in an attempt to map their sense of smell, as well as a unique questionnaire.
The venture, which was launched with backing from Israel’s Ministry of Defense, will be officially promoted in the coming days in Sweden, France, and other countries. The scent test is currently available in English, Hebrew, and Arabic, and expected to be available in Swedish, French, Japanese, Spanish, German, and Persian.
Prof. Noam Sobel’s research is supported by the Azrieli National Institute for Human Brain Imaging and Research, which he heads; the Norman and Helen Asher Center for Human Brain Imaging; the Nadia Jaglom Laboratory for Research in the Neurobiology of Olfaction; the Adelis Foundation; and the Rob and Cheryl McEwen Fund for Brain Research. Prof. Sobel is the incumbent of the Sara and Michael Sela Professorial Chair of Neurobiology.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world’s top-ranking multidisciplinary research institutions. The Institute’s 3,800-strong scientific community engages in research addressing crucial problems in medicine and health, energy, technology, agriculture, and the environment. Outstanding young scientists from around the world pursue advanced degrees at the Weizmann Institute’s Feinberg Graduate School. The discoveries and theories of Weizmann Institute scientists have had a major impact on the wider scientific community, as well as on the quality of life of millions of people worldwide.